RightAnswer Knowledge Solutions provides access to hundreds of data sources. Our premier and proprietary sources include fully-researched documents from well-established experts in the chemical and HazMat fields.
A search in our system for this chemical would return results – all in one place -- in the following categories from the listed data sources.
- Chemical Identification
- Environmental Hazards
- First Aid/Medical Treatment
- Physical/Chemical Properties
- Report Abstracts and Studies
- Reproductive Risk
- Toxicology/Health Hazards/Exposure
|Example of Acute Exposure data from MEDITEXT.|
RightAnswer Proprietary Data Sources:
Other Government Links Searched via RegsKnowledge:
State Environmental Regulations
Example Content from MEDITEXT for 151126-32-8:
Please note: this is an extract of information from a larger document. Full document and details are available by subscription.
ACUTE EXPOSURE INFORMATION
- WITH THERAPEUTIC USE
- The most frequently reported adverse effects, following therapeutic administration of pramlintide, include nausea, vomiting, anorexia, and headache.
- Concomitant administration of pramlintide with one or more antidiabetic agents (eg, insulin, sulfonylureas) increases the risk of hypoglycemia. Severe hypoglycemia associated with pramlintide will generally occur within 3 hours after pramlintide administration.
- WITH POISONING/EXPOSURE
- Pramlintide overdose information is limited. Severe nausea, vomiting, diarrhea, vasodilatation, and dizziness were reported in healthy volunteers following administration of single 10-mg doses.
- Hypoglycemia is not expected after administration of pramlintide alone, but may develop if pramlintide is administered with insulin or other hypoglycemic agents.
© 2011-2020 RightAnswer.com, Inc. and/or its licensors. All rights reserved. No claim to original U.S. Govt. works.